Rheumatoid Arthritis Increases Preterm Birth and Small Infant Risks
Women with rheumatoid arthritis face roughly twice the odds of preterm birth and having infants small for gestational age despite contemporary disease management, a French study shows.
Key Clinical Takeaways:
- Preterm birth occurred in 15.9% of rheumatoid arthritis pregnancies compared to 8.4% in controls.
- Small for gestational age births happened in 20.5% of cases versus 10.9% in the general population.
- Systemic glucocorticoids at doses of at least 10 mg/day during pregnancy independently associated with preterm birth.
Rheumatoid arthritis is a chronic inflammatory disease that commonly affects women during their reproductive years. While earlier research using population data noted elevated risks for negative pregnancy results, those investigations often rely on outdated standards for treating the condition.
To assess the contemporary frequency of adverse pregnancy outcomes and identify associated factors, researchers analyzed data from the prospective French Research Group on Pregnancy and Rare Diseases cohort between 2015 and 2021. The findings were published in the journal RMD Open.
The study analyzed 100 pregnancies in 90 women with rheumatoid arthritis. The average age of the mothers was 33.7 years, and 57.6% of the pregnancies for which parity information was recorded involved women who had not previously given birth.
During pregnancy, 46% of the participants received glucocorticoids, while 39% received biologic disease-modifying antirheumatic drugs. Among the 39 biologic-exposed pregnancies, all but one involved a tumour necrosis factor inhibitor.
Researchers compared 90 pregnancies meeting eligibility criteria with 359 matched pregnancies from the general population. Matching relied on maternal age group, parity, residential area, and singleton or multiple pregnancy status.
Among women with rheumatoid arthritis, 14 of 88 births or 15.9% were preterm. This compared with 8.4% in the matched general population, corresponding to approximately twice the odds of preterm birth with an odds ratio of 2.08.
Small for gestational age births below the 10th percentile occurred in 17 of 83 pregnancies or 20.5%. This compared with 39 of 358 controls or 10.9%, yielding an odds ratio of 2.11.
At the third-percentile threshold, rates reached 6.0% for the study cohort and 2.0% for controls, showing an odds ratio of 3.21. Researchers observed no statistically significant differences for gestational diabetes, caesarean delivery, or macrosomia.
Nulliparity independently associated with small for gestational age birth with an adjusted odds ratio of 3.61. Preterm birth independently associated with increasing maternal age at an adjusted odds ratio of 1.14 per year.
Exposure to systemic glucocorticoids at doses of at least 10 mg/day during pregnancy also independently associated with preterm birth, showing an adjusted odds ratio of 4.91.
Disease activity measured using the Disease Activity Score in 28 joints with C-reactive protein showed no significant association with either outcome. Tumor necrosis factor inhibitor exposure likewise showed no increased risk.
The authors cautioned that residual confounding by indication could not be excluded because higher-dose glucocorticoid use may identify women with more severe or refractory disease. Study limitations included a relatively small cohort, management predominantly in tertiary centres, and substantial missing trimester-specific disease activity data.
The authors concluded that glucocorticoid-sparing strategies and appropriate use of pregnancy-compatible biologic therapies remain potential priorities for improving pregnancy outcomes in these patients.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.